Bicara Therapeutics Inc.
BCAX
$24.28
$0.652.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -55.44M | -56.21M | -37.39M | -36.33M | -27.39M |
| Total Depreciation and Amortization | 44.00K | 44.00K | 43.00K | 24.00K | 19.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.75M | 6.47M | 5.02M | 3.90M | 3.70M |
| Change in Net Operating Assets | 2.43M | 12.19M | 8.44M | 3.16M | -1.93M |
| Cash from Operations | -44.21M | -37.51M | -23.89M | -29.25M | -25.59M |
| Capital Expenditure | -60.00K | -60.00K | -238.00K | -42.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -184.93M | 101.00M | -82.09M | -236.08M | -- |
| Cash from Investing | -184.99M | 100.94M | -82.33M | -236.12M | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.33M | 163.35M | 31.23M | 436.00K | 135.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.33M | 163.35M | 31.23M | 436.00K | 135.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -226.86M | 226.78M | -74.99M | -264.93M | -25.46M |